GeoVax to Conduct Partnering Meetings During BIO International Convention June 4-7
May 22, 2018 09:00 ET
|
GeoVax, Inc.
CEO Robert McNally to Speak as part of BIO’s One Health Day Program ATLANTA, GA., May 22, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human...
VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update
May 01, 2018 08:00 ET
|
VBI Vaccines, Inc.
-- Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac® Hepatitis B Vaccine -- -- Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of...
VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
April 19, 2018 08:00 ET
|
VBI Vaccines, Inc.
More than 1,600 subjects enrolled in PROTECT studyTopline data expected mid-2019 CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”) today announced...
VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine
December 19, 2017 08:00 ET
|
VBI Vaccines, Inc.
Patient dosing commenced on December 18, 20174,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE...
VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
December 12, 2017 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will present at the BMO Capital Markets...
VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares
October 31, 2017 08:30 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million
October 30, 2017 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 Million
October 26, 2017 09:29 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares
October 25, 2017 16:01 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
Assembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea
September 21, 2016 07:30 ET
|
Assembly Biosciences
INDIANAPOLIS, Sept. 21, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus...